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Abstract 
Recent studies have demonstrated in vivo synergistic immunosuppressive and anti-
inflammatory capacity of dexamethasone (Dx) and naproxen (NAP) in collagen-induced 
arthritis (CIA) rats. However, the molecular basis of this synergistic effect is barely 
understood. The low solubility of these drugs and their adverse effects hamper their efficacy 
on the treatment of inflammatory processes making nanoparticulated systems promising 
candidates to overcome these drawbacks. The aim of this work is the preparation of polymeric 
nanoparticles (NPs) that combine NAP and Dx in different concentrations, and the evaluation 
of the expression of key genes related to autoimmune diseases like CIA. To do so, self-
assembled polymeric NPs that incorporate covalently-linked NAP and physically entrapped 
Dx are designed to have hydrodynamic properties that, according to bibliography, may 
improve retention and co-localization of both drugs at inflammation sites. The rapid uptake of 
NPs by macrophages is demonstrated using coumarine-6-loaded NPs. Dx is efficiently 
encapsulated and in vitro biological studies demonstrate that the Dx-loaded NAP-bearing NPs 
are non-cytotoxic and reduce lipopolysaccharide-induced NO released levels at any of the 
tested concentrations. Moreover, at the molecular level, a significant synergistic reduction of 
Il12b transcript gene expression when combining Dx and NAP is demonstrated. 
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1. Introduction 
A recent study demonstrated the additive immunosuppressive and anti-inflammatory effect of 
dexamethasone (Dx) and naproxen (NAP) combined treatment with in vitro and in vivo 
studies on paw edema in female and male Lewis rats with collagen-induced arthritis (CIA). 
[1]
 
Through mathematical models and model simulations authors demonstrated a promising 
steroid-sparing potential of NAP in CIA rats. However, to better understand these results, 
authors emphasize on the need of studying the effect of Dx/NAP combinations at a molecular 
level. CIA is a murine model of rheumatoid arthritis (RA), an autoimmune/inflammatory 
disorder, in which T cells are the primary dysfunctional cells. 
[2]
 Interleukin-12 (IL12) and 
interleukin-23 (IL23) are secreted by macrophages and dendritic cells in response to antigen 
presentation to naïve T cells playing a key role in the differentiation and maintenance of 
autoreactive T cells. 
[3]
 These ILs are dimeric cytokines sharing IL12-p40 subunit which is 
encoded by Il12b gene. 
[4]
 Actual biological treatments based on monoclonal antibodies 
blocking IL12-p40 subunit (e.g. ustekinumab) have demonstrated promising results and low 
side effects if compared with traditional tumor necrosis factor-alpha (TNF-α) inhibitors. [3] 
NAP is a well-known non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, 
antipyretic, and analgesic properties.  It is associated to the lowest cardiovascular risk of all 
NSAIDs 
[5]
 and its half-life is more than ten times higher than that of other NSAIDs. 
[6, 7]
 NAP 
derivatives have recently demonstrated capacity to inhibit IL12 production. 
[8]
 However, NAP 
is not a disease modifying drug when used alone, thus it is frequently combined with other 
drugs for the treatment of inflammatory processes. Dx is one of the most frequently used 
therapeutic glucocorticoids. Owing to its immunosuppressive, and anti-inflammatory capacity, 
it has demonstrated great potential for the treatment of RA, 
[1]
 Alzheimer, 
[9]
 or inflammatory 
Bowel disease. 
[10]
 At low doses (i.e. below 100nм) Dx treatment leads to polarization of in 
vitro cultured macrophages to M2 anti-inflammatory phenotype 
[11, 12]
 whereas at higher doses 
Dx (approx. 1 μM) treatment leads to trans-repression of genes encoding pro-inflammatory 
cytokines like IL12-p40 subunit 
[13]
 and reduces vascular endothelial growth factor (VEGF) 
expression, 
[14-16]
 a major contributor to macrophages-derived angiogenic activity. 
[17]
 Both 
drugs are first-line therapies for inflammation-related diseases because of their rapid 
symptomatic effects. 
[5, 18]
 However, their sustained use is limited by their high 
hydrophobicity, the rapid clearance of free drug from inflammation sites by the lymphatic 
system and the dose and time-dependent adverse effects. 
[5, 18, 19]
  It has been well-established 
the enhanced therapeutic potential of nanomedicines over freely administered drugs. If they 
are properly designed, they preferentially accumulate in the pathological tissue providing a 
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better spatial and temporal localization of the drug, and increasing its activity while reducing 
its adverse effects. 
[20]
 Features like leaky vasculature or acidic pH characterize the inflamed 
microenvironment when compared with healthy tissue and they can be exploited to favor drug 
accumulation at inflamed areas. 
[19]
 Matsumura et al. described for the first time that long-
circulating macromolecules undergo passive accumulation in the inflamed tissue as they do in 
tumor sites through a mechanism similar to Enhanced Permeability and Retention (EPR) 
effect known as Enhanced Leaky Vasculature and Inflammatory cells Sequestration (ELVIS) 
effect. 
[21]
 This name owes to the leaky vasculature that allows preferential accumulation at 
inflamed areas and the need of sequestration by inflammatory cells to avoid rapid clearance of 
the macromolecules or nanocarriers by lymphatic drainage which is not present in tumors. 
Consequently, retention at inflamed tissue can be improved by tailoring nanoparticles (NPs) 
hydrodynamic properties (e.g. size and surface charge). Cheng et al. 
[22]
 reported that NPs 
with diameter below 100 nm are easily cleared by lymphatic vessels and Awaad et al. 
[23]
 
concluded that 95-200 nm is the ideal size for increased cellular uptake.  Moreover, NPs 
presenting positive surface charge showed higher cellular uptake when compared to neutral or 
anionic particles due to the ionic attraction between cationic charges and negatively charged 
phospholipids that composes the cell membrane. 
[24, 25]
 Therefore, the aim of this work was 
the preparation of polymeric NPs that combine NAP and Dx in different concentrations, and 
the evaluation of the expression of key genes related to autoimmune diseases like CIA. Self-
assembled polymeric NPs that incorporate covalently-linked NAP and physically entrapped 
Dx were obtained with amphiphilic gradient copolymers presenting appropriate 
microstructure and hydrophilic/hydrophobic balance to self-assemble in aqueous media. 
Hydrodynamic properties of the NPs (i.e. size, polydispersity and, surface charge) were 
optimized as a function of pH, NPs final concentration ([NPs]F), and final volume (VF) to 
favor retention and co-localization of both drugs at inflammation sites. Stability studies over 
time were also carried out. Dx was encapsulated and the encapsulation efficacy and loading 
capacity were determined by HPLC. Finally, RAW264.7 murine macrophages were used as 
model inflammatory cells. With no further stimuli, they are inactivated macrophages with 
predominant M0 phenotype. Activation with pro-inflammatory molecules such as 
lipopolysaccharide (LPS) leads to polarization to M1 and overproduction of NO, TNF-α, and, 
in particular, IL23, and IL12, which are associated to the pathogenesis of autoimmune 
diseases like CIA. On the contrary, activation with molecules such as Dx polarize 
macrophages to M2-phenotype 
[11]
 leading to overproduction of VEGF, interleukin-10 (IL10) 
or tumor growth factor-beta (TGF-β) (scheme 1). [26] According to that, in vitro biological 
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studies with RAW264.7 macrophages were carried out to evaluate rapid uptake of NPs, 
cytotoxicity and anti-inflammatory capacity of the system. Anti-inflammatory properties were 
evaluated via NO-released levels quantification using Griess reagent and levels of expression 
of Il12b, Il23a and Tnfa transcripts by RT-qPCR (Scheme 1). The transcript expression levels 
were assessed under non-activated normal tissue conditions to discard that the positively 
charged NPs could induce M1-like polarization through toll-like receptor 4 signaling causing 
toxicity by interacting with cellular components. 
[26, 27]
 Additionally, levels of expression of 
M2 and angiogenesis markers were evaluated after treatment with Dx-loaded systems. And 
finally, the expression levels of M1 markers were assessed under simulated inflammatory 
tissue conditions (i.e. after LPS activation of macrophages). 
 
Scheme 1: schematic presentation of the polarization of murine macrophages in response to 
lipopolysaccharide (LPS) or dexamethasone (Dx) activation and the relation of M1- and M2-
marker genes under study in this work. 
 
2. Results and Discussion 
2.1 Synthesis and characterization of the methacrylic derivative of naproxen (HNAP)  
A methacrylic derivative of NAP (HNAP) was successfully synthesized (Scheme 1a) in mild 
conditions with yields above 90% and high purity after a simple purification procedure as 
confirmed by 1H-NMR spectroscopy (figure 1). The linkage of NAP through the carboxylic 
group might improve safety profile as it has been reported as the main contributor to 
gastrointestinal adverse effects. [28] The resultant ester linkage is prone to hydrolysis under 
acidic conditions encountered in inflamed tissues where the pH is one point lower than 
physiological pH (i.e. about 6.4) [21] and in lumen of lysosomes whenever sequestration by 
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inflammatory cells occurs. [29] Altogether may provide a pH-accelerated release of NAP at the 
inflamed area.  
 
 
Figure 1. 
1
H-NMR spectrum of the product of the naproxen-based monomer synthesis. 
HNAP: 
1
H NMR (400 MHz, CDCl3) δH 7.66 – 7.51 (m, 3H), 7.32 (dd, J = 8.5, 1.9 Hz, 1H), 
7.12 – 6.98 (m, 2H), 5.87 (dq, J = 1.9, 1.0 Hz, 1H), 5.37 (p, J = 1.6 Hz, 1H), 4.32 – 4.13 (m, 
4H), 3.84 (s, 4H), 1.74 (dd, J = 1.6, 1.0 Hz, 3H), 1.51 (d, J = 7.2 Hz, 3H). 
2.2 Synthesis and characterization of copolymers of naproxen-based methacrylic 
monomer and 1-vinyl imidazole, poly(HNAP-co-VI). 
Previous works in our group have demonstrated that an amphiphilic gradient microstructure is 
obtained when copolymerizing low reactive vinylic monomers (e.g. vinyl-imidazole (VI)) and 
highly reactive methacrylic ones (e.g. HNAP) by free radical copolymerization. [30-32] 
Moreover, if the hydrophobic-hydrophilic balance is the appropriate one this microstructure 
may self-assemble into NPs in aqueous media having a hydrophobic core mainly formed by 
covalently linked NAP and a hydrophilic shell mainly formed by VI. [31] As VI also presents 
protonable amine groups it may provide the desired positive surface charge to favor 
internalization by inflammatory cells. Accordingly, macromolecules with two different 
molecular weights and 0.2, 0.5 and 0.8 feed molar composition of HNAP were prepared in 
order to determine the most appropriate molecular weight and hydrophobic-hydrophilic 
balance. The obtained copolymers are labeled according to their molecular weight (HMW or 
LMW) followed by their molar content in HNAP obtained by 1H-NMR. The chemical 
reactions carried out for the synthesis of HNAP a) and the copolymers b) are illustrated in 
Scheme 2.  
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Scheme 2. Synthesis of a) the hydrophobic methacrylic derivative of naproxen (HNAP) 
through a carbodiimide mediated Steglich esterification reaction and; b) the copolymer 
poly(HNAP-co-VI) via free radical polymerization reaction in solution. 
HNAP was successfully co-polymerized with VI by free radical polymerization for all feed 
molar ratios as confirmed by the disappearance of the  1H-NMR signals corresponding to the 
vinyl protons of both monomers (CH2-VI at 4.9 and 5.45 ppm and CH2-HNAP at 5.6 and 5.9 
ppm), the new 1H-NMR signals resultant from the methylene protons of the backbone chains 
(CH3-m, CH2-l and CH2-n between 0.1 and 2.8 ppm) and the broadening of the signals as a result 
of the macromolecular nature of the copolymer (figure 2). The copolymers molar 
composition was quantitatively determined from their corresponding 1H-NMR spectra by 
considering the signals between 0.1 and 2.8 ppm assigned to 8 protons of HNAP (CH3-m, CH3-
i and CH2-l) and 2 protons of VI (CH2-n) and the signals between 6.5 and 8.0 ppm resultant 
from 6 aromatic protons of HNAP (CH-b-g) and 3 aromatic protons of VI (CH-p,q,r).  
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Figure 2. 1H-NMR spectrum of HNAP71 copolymer and the integrals used to compute 
copolymer molar composition. p(HNAP-co-VI) (71-29; HNAP-71): 1H NMR (400 MHz, DMSOd6) 
δH 7.89−6.45 (m, 9H (3VI + 6HNAP)), 4.53−3.39 (m, 8H (8HNAP)), 3.22-2.73 (s, 1H (1VI)), 
2.28−0.10 (m, 10H (2VI + 8HNAP)) 
HNAP feed molar composition (FHNAP), homopolymer and copolymer HNAP molar 
composition (fHNAP), reaction yields, average molecular weight (Mw), polydispersity index (Đ) 
and glass transition temperature (Tg) of the synthesized copolymers are summarized in table 
1.  
 
Table 1. Summary of the main results of the physicochemical characterization of high and 
low molecular weight copolymers and homopolymers. 
 Polymer F
HNAP
a)
 f
HNAP
b) 
Yield [%] M
w
c)
 [kDa] Ɖ
d)
 T
g
e)
 
[°C] 
HMW 
H-pVI 0.00 0.00 22 26 1.3 177 
H-HNAP26 0.20 0.26 43 164 1.6 82 
H-HNAP60 0.50 0.60 76 249 1.8 75 
H-HNAP84 0.80 0.84 96 331 1.9 58 
H-pHNAP 1.00 1.00 94 343 2.0 56 
LMW 
L-pVI 0.00 0.00 33 33 1.6 184 
L-HNAP24 0.20 0.24 72 62 1.9 84 
L-HNAP71 0.50 0.71 75 75 2.0 67 
L-HNAP85 0.80 0.85 77 83 1.9 58 
L-pHNAP 1.00 1.00 84 96 2.3 57 
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a)Molar fraction of HNAP in the feed, b)molar fraction of HNAP in the copolymer, c)Molecular weight, 
d)Polidispersity of molecular weight distribution and e)glass transition temperature 
The polymerization successfully occurred in the whole range of compositions and with both 
initial monomer concentrations tested. Copolymers with molecular weights below 100 KDa 
were obtained when using a monomer initial concentration of 0.25 м and copolymers with 
molecular weights above this value resulted when using twice this initial monomer 
concentration as expected for a free radical copolymerization reaction. [33] The differences 
among copolymer HNAP molar content (fHNAP) and feed HNAP molar content (FHNAP) can be 
attributed to the differences on the chemical reactivity of the monomers (see next section), 
and because total conversion of the polymerization was not reached. Moreover, it has been 
reported that copolymerization at high concentrations of VI are accompanied by a mild 
degradative addition reaction that depends on the interaction of the VI ring with the 
propagating radicals. [34] These relative degradative addition reactions may explain the low 
yields and low polydispersity indexes obtained for copolymers with higher FVI and the 
increasing trend of molecular weights as FHNAP increases being this effect more significant in 
high monomer concentration reactions (i.e. HMW). Polydispersity index values and yields 
approaches to the typical ones for a conventional radical polymerization process as FHNAP 
increases. According to the obtained reactivity ratios (see next section) a pseudoblock 
microstructure was obtained, however only one Tg between the range of the Tg values of both 
homopolymers (i.e. pHNAP and pVI) was detected for all copolymers. This result indicates 
that microphase segregation was not produced or was not detected by the applied DSC 
method.  
2.3 Determination of Reactivity Ratios: Microstructural Analysis 
Reactivity ratios are kinetic parameters which measure the relative rate of addition of each 
comonomer to a growing copolymer chain and they allow the estimation of the copolymer 
average composition and the monomer sequence distribution. Those comonomers that differ 
in hydrophilicity and present very different reactivity ratios give rise to amphiphilic gradient 
microstructure by free radical copolymerization. [30, 32] Accordingly, the most reactive one is 
incorporated first and the least reactive one is incorporated at the last stages of the 
copolymerization reaction. These copolymers self-assemble in aqueous media leading to 
supramolecular structures (e.g. NPs). Reactivity ratios of the co-monomers (rHNAP and rVI) 
were determined by in situ 1H-NMR monitorization of the copolymerization reaction at three 
different feed molar compositions by following the disappearance of the vinyl protons signals 
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of both co-monomers, as previously described by Aguilar et al. [35] The data obtained were fit 
to a well-known integrated form of the differential copolymer equation defining the terminal 
model:  
[𝐻𝑁𝐴𝑃]𝑡 =  [𝐻𝑁𝐴𝑃]𝑜 × (
[𝑉𝐼]𝑡 /[𝐻𝑁𝐴𝑃]𝑡
[𝑉𝐼]𝑜 /[𝐻𝑁𝐴𝑃]𝑜
)
𝑟𝑉𝐼
1−𝑟𝑉𝐼
×  (
1 − 𝑟𝑉𝐼 + (𝑟𝐻𝑁𝐴𝑃 − 1)[𝑉𝐼]𝑡
1 − 𝑟𝑉𝐼 + (𝑟𝐻𝑁𝐴𝑃 − 1)[𝑉𝐼]𝑜
)
(𝑟𝐻𝑁𝐴𝑃𝑟𝑉𝐼)−1
(1−𝑟𝐻𝑁𝐴𝑃)(1−𝑟𝑉𝐼)
 
 
 
Being [M]t and [M]o the molar concentration of monomer M at time t and the initial monomer 
concentration, respectively; and rM the reactivity ratio of monomer M.  The obtained reactivity 
ratios were rHNAP = 3.16 ± 1.2 and rVI = 0.31 ± 0.06 meaning that active radicals incorporate 
HNAP monomer around 10 times faster than VI. These values were consistent with 
previously reported copolymerization reactions between VI and methacrylic derivatives using 
AIBN as free radical initiator 
[34, 36]
 and they revealed that the desired gradient microstructure 
is obtained. Figure S1 shows the surface copolymerization diagram representing the 
instantaneous HNAP incorporation to the growing chain as a function of conversion and 
HNAP feed molar composition. Macromolecules rich in the most reactive monomer (HNAP) 
are formed at low conversions, and after most HNAP is consumed, VI-rich copolymer chains 
are formed. Few chains with intermediate compositions are obtained. 
2.4 Preparation and characterization of self-assembled polymeric nanoparticles. 
NPs were obtained by nanoprecipitation method in aqueous media for all the prepared 
copolymers. Results of hydrodynamic diameter (Dh, by intensity) and polydispersity index 
(PdI) obtained by DLS and zeta potential (ξ) values obtained by LDE are summarized in table 
2.  
 
Table 2. Hydrodynamic properties of nanoparticles based on HNAP26, HNAP60, HNAP84, 
and HNAP24, HNAP71, and HNAP85 measured by Dynamic Light Scattering and Laser 
Doppler Electrophoresis. 
 Copolymer D
h
a)
 [nm] PdI
b)
 ξ
c)
 [mV] 
HMW 
NP-H-HNAP26 140.3 ± 7.8 0.358 ± 0.058 + 23.8 ± 1.8 
NP-H-HNAP60 180.3 ± 3.5 0.366 ± 0.058 + 32.2 ± 0.9 
NP-H-HNAP84 231.5 ± 9.2 0.498 ± 0.084 + 39.3 ± 1.0 
LMW 
NP-L-HNAP24 90.6 ± 1.3 0.175 ± 0.015 + 25.3 ± 0.8 
NP-L-HNAP71 140.2 ± 2.1 0.181 ± 0.002 + 28.8 ± 0.7 
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NP-L-HNAP85 191.0 ± 6.8 0.375 ± 0.054 + 40.6 ± 0.8 
a)
Hydrodynamic diameter, 
b)
Polydispersity Index and 
c)
z-potential 
 
NPs were labeled as the copolymers that were used in their preparation. High molecular 
weight copolymers did not lead to the formation of stable NP because of their poor solubility 
in the organic phase. Both copolymer composition and molecular weight played a key role in 
the NP stability and polydispersity, being PdI>0.3 for all the NP obtained with HMW 
copolymers. The formation of stable NPs was only feasible for LMW formulations with fHNAP 
lower than 0.80. HNAP85-based NPs and NPs based on HMW copolymers presented high 
polydispersity indexes and precipitation of the copolymer was observed shortly after 
preparation. VI is located at the surface of the NPs as indicated by the positive surface charge. 
Moreover, the ξ values around + 30 mV for the HNAP71-based formulation are indicative of 
good stability in suspension. 
[37]
 NP-L-HNAP71 showed spherical morphology (figure 3), a 
hydrodynamic diameter of 140 nm (i.e. between 100 and 200 nm), and positive surface charge 
(ξ = +28.8 mV). Therefore NP-L-HNAP71 presented the most suitable hydrodynamic 
properties for passive accumulation 
[22, 38]
 and improved retention at inflamed areas 
[24, 25]
 
according to bibliography.  
 
Figure 3. Scanning Electron Microscopy micrograph showing morphology of NP-L-HNAP71. 
 
NP diameter slightly varied (i.e. ± 5-10 nm) with [NPs] on the aqueous phase or with final 
volume keeping the values within the ranges that facilitate their sequestration by 
inflammatory cells. However, the particles diameter significantly increased up to 20 nm when 
the concentration of copolymer in the organic phase changes from 10 mgmL
-1
 to 15 mgmL
-1
 
(table 3).   
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Table 3. Hydrodynamic properties of nanoparticles based on HNAP71 at different final 
concentration of nanoparticles in the aqueous phase and at different final volumes. 
 
[NPs]
A.P.
a)  
[mgmL
-1
] 
V
F
 (mL) 
[HNAP71]
O.P.
b)
 
[mgmL
-1
] 
D
h
c) 
[nm] PdI
d)
 ξ
e)
 [mV] 
1.0  
10 10 140.2 ± 2.1 0.181 ± 0.002 28.8 ± 0.7 
20 10 126.6 ± 1.4 0.186 ± 0.021 27.8 ± 0.1 
30 10 132.1 ± 1.6 0.173 ± 0.023 30.6 ± 1.4 
5.0 
10 10 129.5 ± 0.2 0.164 ± 0.025 31.2 ± 1.5 
20 10 131.7 ± 1.3 0.165 ± 0.021 29.3 ± 0.8 
30 15 150.0 ± 2.9 0.197 ± 0.016 28.8 ± 1.2 
a)
Concentration of NPs in the aqueous phase and 
b)
concentration of the copolymer in the 
organic phase 
c)
hydrodynamic diameter, 
d)
polydispersity and 
e)zeta potential 
 
VI ionizable groups played a key role in the NP stability as a function of pH. Figure 4a shows 
the size distribution and the ξ values of the HNAP71 nanoparticulated system at different pH. 
When pH 5.0 is reached, it is observed a broadening of the size distribution and a significant 
increase in the intensity of the peak in the microscale suggesting the agglomeration of NPs 
that may be attributed to the decrease in the surface charge and, hence, to the reduction of the 
electrostatic repulsion between particles as the pH approaches to the pKb of VI (pKb = 5.0-6.0). 
The phenomenon is partially reversible as when pH was reduced to 4.0 original hydrodynamic 
properties are recovered. Based on these results and on the previously reported strong 
buffering capacity of VI, 
[39, 40]
 it was necessary the use of 0.1 м Acetic Acid to keep pH value 
constant avoiding NPs agglomeration and maintaining their stability over time. Figure 4b 
shows that there are no significant changes on the hydrodynamic properties of HNAP71 NPs 
obtained at pH 4 and stored during 4 weeks at 4 ºC.  Furthermore, NPs recover their initial 
hydrodynamic properties after freeze-drying and dispersion in the buffer solution at pH 4.0 
only if they are sonicated for 10 minutes with an ultrasound tip (30% amplitude) (figure 4c). 
Therefore, size and morphology of the particles could be modulated by controlling the molar 
composition of the copolymers and the concentration of copolymer in the organic phase and 
NPs can be stored at 4 ºC and pH 4.0 for at least one month or in powder.  
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Figure 4. Size distribution (by intensity) and z-potential (ξ) of NPs based on HNAP71 
measured a) at different pH values, b) at pH 4 and 4 ºC for different periods of time and; c) 
before freeze-drying (dashed line) and after freeze-drying and tip sonication for 10 minutes 
(solid line).  
 
2.5 Dexamethasone loaded NPs 
Dx was encapsulated in NP-L-HNAP71 with encapsulation efficacy of 8% and loading 
capacity of 2% showing a diameter increase of 18 nm which translates into a reduction on the 
surface area-to-volume ratio and hence, lead to a decrease of the surface charge (table 4).  
Table 4. Summary of encapsulation efficiency, loading capacity and hydrodynamic properties 
of unloaded and, dexamethasone-loaded nanoparticles prepared with L-HNAP71 copolymer 
 
a)
Encapsulation Efficiency,
 b)
Loading capacity, 
c)
hydrodynamic diameter, 
d)
polydispersity and 
e)zeta potential 
Acronym Sample EE
a)
 [%] LC
b)
 [%] D
h
c) [nm] PdI
d)
 ξ
e)
 [mV] 
NAP NPs NP-L-HNAP71 - - 131.5 ± 3.3 0.115 ± 0.016 + 28.8 ± 0.7 
8Dx-NAP NPs 8Dx-NP-L-HNAP71 8  2.00 149.5 ± 1.8 0.085 ± 0.018 + 26.1 ± 0.9 
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2.6 Uptake of c6-labelled NPs by macrophages 
 
Figure 5. a) Fluorescence micrograph of c6-NAP NP internalized by RAW264.7 
macrophages; and b) quantification of the internalized c6 by RAW264.7 when treated with 
c6-NAP NP for different periods of time. The diagram includes the mean and the standard 
deviation (n = 3). 
Fluorescent c6-loaded NPs (table S1) were used to monitor cellular internalization by 
RAW264.7 macrophages over 24h of exposure. Figure 5 shows that the NPs uptake by 
RAW264.7 macrophages increases linearly over time and fluorescence images confirmed the 
successful internalization of the NPs when in suspension. These results are in accordance with 
recently reported fast uptake of NAP-containing NPs by THP1-derived macrophages. 
[41]
 The 
uptake of nanoparticles by inflammatory cells is critical to retain them in the inflamed tissue 
and, in this work, hydrodynamic properties were adjusted to enhance the ELVIS effect 
according to bibliography, i.e. hydrodynamic diameters between 100 and 200, positive zeta 
potential, and spherical shape. 
[22-25]
 
2.7 In vitro cytotoxicity assay of NPs 
Cytotoxicity of 8Dx-NAP NPs was studied and compared with the free Dx at a concentration 
equal to the Dx encapsulated in 8Dx-NAP (i.e. 56.66 μм of Dx per 1 mgmL-1 of NPs) and 
NAP NP using RAW264.7. None of the assayed NP or Dx concentrations resulted on a 
reduction in viability of RAW264.7 higher than 30% (ISO 10993-5:2009) after 24h. 8Dx-
NAP NPs (dashed white) and unloaded NAP NPs (black) formulations showed non-
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statistically significant differences (*p < 0.05) with respect to the control (CP i.e. cells in 
culture medium, LPS-) at any of the tested concentrations but the highest one (0.25 mgmL
-1
) 
in case of NAP NPs and the two highest ones (0.25 and 0.125 mgmL
-1
) in case of 8Dx-NAP 
NPs. However, free Dx (red) presented significant differences with the control at all tested 
concentrations.  These results suggest that encapsulated Dx presents lower cytotoxicity than 
free-Dx (figure 6), however, no statistically significant differences were found between these 
two groups after 24h of incubation.  
 
Figure 6. Cell viability of RAW264.7 macrophages treated with different concentrations of 
unloaded NPs (NAP NPs, black), Dx-loaded NAP NPs (8Dx-NAP NPs, white) or free Dx 
(red) over 24h. The diagrams include the mean, the standard deviation (n = 8), and the 
ANOVA results (*p < 0.05 statistically significant difference with cells treated with media 
(LPS-, top of the bars) and between the different systems (brackets): NAP NPs, 8Dx-NAP 
NPs and free Dx). 
2.8 In vitro anti-inflammatory and anti-angiogenic activity of NPs 
Nitric Oxide (NO) assay  
LPS-induced NO release was measured after 24h of LPS administration and challenged with 
different concentrations of 8Dx-NAP NPs, unloaded NAP NPs or free Dx (figure 7). 
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Figure 7. NO release by RAW264.7 macrophages after 24 h with no treatment (LPS-), 
treatment with LPS alone (LPS+), and treatment with LPS and different concentrations of 
unloaded NAP NPs (black), 8Dx-NAP NPs (white) or free Dx (red) suspension. The diagrams 
include the mean, the standard deviation (n = 8), and the ANOVA results (*p < 0.05 and **p 
< 0.01 statistically significant difference with LPS+ cells (on top of the bars) or between NAP 
NPs, 8Dx-NAP NPs and free Dx (brackets)). 
 
After 24h of incubation, free Dx and 8Dx-NAP reduced NO release in a statistically 
significant manner at all tested concentrations whereas unloaded NAP NPs counteract LPS-
induced NO release in a statistically significant (*p < 0.05) way with respect to LPS treated 
cells (LPS+) at all concentrations but 0.09 and 0.045 mgmL-1 (figure 7). At NPs 
concentration between 0.125 and 0.023 mgmL-1, it is observed a statistically significant (*p < 
0.05) reduction of NO released levels when comparing unloaded NAP NPs and 8Dx-NAP 
NPs. Moreover, for this range of concentrations 8Dx-NAP NPs and free Dx present non-
significant differences in terms of reduction of % NO-release. These results demonstrate that 
encapsulation does not diminish Dx capacity to reduce NO-release levels at NPs 
concentrations between 0.125 and 0.023 mgmL-1. A concentration of NP of 0.045 mgmL-1 
was chosen for further experiments as it was the lowest non-toxic concentration of NPs in 
which most significant differences between unloaded NPs and Dx-loaded NPs were observed. 
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Reverse transcription, real-time quantitative PCR (RT-qPCR) analysis 
Figure 8a and figure 8b, respectively, show the fold change in transcript levels of Tnfa, 
Il12b and Il23a (M1 markers) and Vegfa (angiogenesis and M2 marker), Tgfb1 and Il10 (M2 
markers) determined by RT-qPCR after 1 day and 7 days of treatment. Results are expressed 
relative to the corresponding level of expression of each transcript in the untreated sample (i.e. 
only culture media, LPS-) and they are the graphical presentation of the mean and standard 
deviation (mean ± SD, table S2) of two independent samples (n = 2). The heat map in figure 
8c showed that after 24h of treatment with 8Dx-NAP NPs or NAP NPs, all M1 markers were 
under-expressed (green) or equally expressed (black) when compared to the untreated sample 
showing no M1-polarization at this time point. In contrast, all genes but Il12b were 
overexpressed (red) after 7 days post treatment with any of the nanoparticulated systems 
tested. However, the statistical analysis revealed no significant differences in the expression 
of Tnfa or Il23a between systems and that only Tnfa expression and IL23a expression after 7 
days of treatment with Dx-loaded NPs and free Dx, respectively, were significantly higher 
when compared to the untreated sample (LPS-). The Tnfa increased level after long-term 
treatment might be related with the presence of an NSAID in the system, an extensively 
reported effect related to important gastrointestinal side effects. 
[42]
  Basically, NSAIDs 
counteract prostraglandin-E2 (PGE2) overproduction and hence, reduce PGE2 positive 
feedback on TNF-α level. [43] This effect was not observed after 24 hours of treatment as with 
other previously described free NSAIDs treatments. 
[44]
 However, after 7 days, Tnfa levels 
increased in an evident and comparable manner for the three systems under study and 
significant differences with respect to the untreated control (LPS-) were only observed for the 
system combining NAP/Dx. Therefore, the linkage of the NSAID to the polymeric structure 
and its controlled release delays the onset of this response whereas Dx encapsulation did not 
counteract it. In fact, this effect is even increased by NAP/Dx combination because Dx is a 
glucocorticoid that inhibits phospholipase A2, an upstream mediator in the production of 
prostaglandins from arachidonic acid, and hence, it can ultimately contribute to a further 
reduction of PGE2 levels. 
[45]
 All in all, the most interesting result was the almost knockdown 
of Il12b expression when treating RAW264.7 macrophages with 8Dx-NAP NPs. According to 
the heat map, Dx in its free form inhibited Il12b expression levels at both time points tested. 
NAP NPs also inhibit Il12b expression (1 day) or kept it at basal levels (7 days). However, 
statistically significant differences were only observed after treatment with the Dx/NAP 
nanoparticulated system. In fact, there was a clear synergistic effect in the trans-repression of 
this gene when encapsulating Dx in NAP-bearing NPs. It has been reported that Il12b
-/- 
mice 
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are completely protected from CIA. 
[46]
 Therefore, if this synergistic repression of Il12b 
occurs also under inflammatory conditions, it might be the reason for the Dx dose-sparing 
capacity of NAP in the treatment of this disease. On the other hand, figure 8b shows that, as 
expected, no statistically significant over-expression of M2 markers is observed for either free 
Dx or encapsulated Dx (2.55 μм) as the concentration of Dx is higher than 100 nм which is 
the reported limit concentration for polarization. 
[12]
 At concentrations higher than 100 nм, Dx 
is expected to reduce VEFG expression, a major contributor to macrophage-derived 
angiogenic activity, 
[17]
 and also Il10 expression contributing to reduction of allergic 
inflammation in the treatment of allergic diseases. 
[47]
 This anti-angiogenic capacity described 
for Dx in several cell lines 
[15, 48]
 is clearly observed after 7 days when it is in its free form 
(free Dx) but not when encapsulated (8Dx-NAP-NPs). The same occurs with the Il10 
transrepression which was clearly observed in Dx on its free form at both time points studied 
but was not occurring when cells were treated with 8Dx-NAP-NPs instead. Therefore, 
encapsulation and controlled release of the drug or its combination with NAP is causing 
retardation or suppression of anti-angiogenic activity and transrepression of Il10. The 
reduction of Il10 repression caused by Dx when combining it with NAP might be related to 
the observed synergistic repression of Il12 as it has been reported that blockage of IL10 
translates into IL12 overproduction. 
 
Figure 8. Quantitative real-time PCR data. Fold change in gene expression levels with respect 
to control (cells treated with medium, LPS-) of a) M1 markers or b) M2 markers in non-
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inflamed samples treated with free dexamethasone (free Dx, 2.55 μм), Dx-loaded naproxen-
bearing NPs (8Dx-NAP NPs, 2.55μм Dx and 0.045 mgmL-1  NPs) and unloaded naproxen-
bearing NPs (NAP NPs, 0.045 mgmL
-1
) for 1 day or 7 days. Results are expressed relative to 
the corresponding level of expression of each transcript in the untreated sample (i.e. only 
culture media). Data are presented as mean fold changes in gene transcript levels (mean ± 
standard deviation) in two independent biological samples per system (three experimental 
replicates per biological sample), and the ANOVA results (# - comparison between day 1 and 
day 7 conditions, #p < 0.05 and ###p < 0.001; * - comparison between systems at the same 
time point, **p < 0.01 and ***p < 0.001). 
 
Finally, as Il12b is primarily produced by activated macrophages, to confirm Dx/NAP 
synergistic effect under simulated inflammatory conditions, macrophages are polarized to M1 
pro-inflammatory phenotype by LPS-stimulation. 
[49]
 At the same time, they are treated with 
either culture media (LPS+), free Dx (2.55 μм), unloaded NPs (0.045 mgmL-1) or Dx-loaded 
NPs (2.55μм Dx and 0.045 mgmL-1 NPs). Again, the expression of M1 marker genes was 
expressed relative to the corresponding level of expression of each transcript in the untreated 
sample (figure 9). When comparing to the inflamed control (LPS+), after 24 hours of 
treatment with NAP NPs transcript levels of pro-inflammatory cytokines were not altered. 
However, free Dx and 8Dx-NAP NPs treatment significantly reverse M1 polarization. 
Therefore, the short-term activity of the system is attributed to Dx release. Moreover, the 
system combining covalently linked NAP and physically entrapped Dx (8Dx-NAP NPs) 
reduced in a highly significant manner the levels of Il12b at both time points reproducing the 
previously obtained results in normal tissue conditions. The significantly increased expression 
levels of Tnfa that is clearly observed in Dx/NAP combining system might also play a role on 
Il12b synergistic repression. Some authors reported that this increase in Tnfa is not 
necessarily pathogenic but it could be beneficial as it regulates adaptive immune response via 
inhibition of IL12 and IL23. 
[50]
 These results support this affirmation and suggest that Tnfa 
induced inhibition of IL12 and IL23 occurs through repression of Il12b gene, a gene codifying 
for IL12-p40 subunit. 
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Figure 9. Quantitative real-time PCR data. Gene transcript levels of M1 markers in inflamed 
samples (500 ng/mL of LPS) treated with just LPS (LPS+) or LPS and free dexamethasone 
(free Dx, 2.55 μм), Dx-loaded naproxen-bearing NPs (8Dx-NAP NPs, 2.55 μм Dx and 0.045 
mgmL
-1
 NPs) and unloaded naproxen-bearing NPs (NAP NPs, 0.045 mgmL
-1
) for 1 day or 7 
days. Results are expressed relative to the corresponding level of expression of each transcript 
in the untreated sample (LPS-). Data are presented as mean fold changes in gene transcript 
levels (mean ± standard deviation) in two independent biological samples per system (three 
experimental replicates per biological sample), and the ANOVA results (# - comparison with 
LPS+ control, #p < 0.05 and ###p < 0.001; * - comparison with untreated LPS- control, *p < 
0.05, **p < 0.01 and ***p < 0.001) 
 
The study at the molecular level of the expression of specific markers of autoimmune diseases 
confirmed that the combination of NAP and Dx translates into a synergistic reduction of Il12b 
transcript levels either in normal or inflammatory conditions. Il12b gene transcribes for the 
IL12-p40 subunit that is common for IL12 and IL23. IL12 is decisive in regulating lineage 
commitment to T helper 1 cells (Th1) development, whereas IL23 is essential for the 
maturation and stability of IL17-producing T helper 17 cells (Th17). 
[46]
 Therefore, Dx/NAP 
combination and, in particular, the newly described Dx-loaded NAP bearing NPs have 
potential for the treatment of diseases in which IL12 and IL23 are overexpressed and Th1 and 
Th17 play a key role in pathogenesis. That is the case of autoimmune/inflammatory disorders 
like Crohn’s disease, ulcerative colitis, psoriatic arthritis, rheumatoid arthritis, human multiple 
sclerosis, psoriasis… [51, 52] This combination of FDA-approved drugs acts at a genetic level 
inhibiting Il12b expression levels by macrophages, a IL12-p40 subunit codifying gene, and, 
hence, decreasing IL12 and IL23 levels. This could offer an alternative to an antibody 
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(Sterala© (ustekinumab)) recently approved by the FDA for the treatment of Crohn’s disease, 
psoriasis, psoriatic arthritis and plaque psoriasis. This monoclonal antibody blocks IL12-p40 
subunit preventing IL12 and IL23 binding to their receptors. 
[53, 54]
 
 
3. Conclusions 
New self-assembled bioactive NAP-containing polymeric NPs loaded with Dx were 
successfully prepared. Hydrodynamic properties and surface charge were optimized to favor 
accumulation and retention at inflamed areas. In vitro biological tests with RAW264.7 
macrophages demonstrated fast sequestration of c6-loaded NPs. Moreover, the system was 
non-cytotoxic and Dx encapsulation does not compromise the NO reduction capacity at any of 
the tested concentrations. Finally, the most interesting result was the synergistic reduction of 
Il12b transcript levels when combining Dx and NAP. A clear Dx dose-sparing capacity of 
NAP was observed in terms of Il12b repression which makes this combination highly 
interesting in the treatment of autoimmune/inflammatory diseases in which IL12 or IL23 are 
overexpressed and Th1 and Th17 cells play a key role in pathogenesis. This drug delivery 
system has been designed, according to bibliography, to have potential to achieve better 
spatiotemporal localization of Dx/NAP combination at inflamed areas and, by the synergistic 
reduction of Il12b transcript levels, to improve the treatment of a wide range of autoimmune 
diseases. 
 
4. Experimental Section 
Synthesis and characterization of the methacrylic derivative of naproxen (HNAP). The 
synthesis of the HNAP was carried out through a carbodiimide mediated Steglich 
esterification reaction 
[55]
 (Scheme 1) as previously described by our group for the methacrylic 
derivative of ibuprofen. 
[31]
 Briefly, NAP (1 equiv) was dissolved in dichloromethane (DCM, 
Aldrich) and subsequently, purified hydroxyethyl methacrylate (HEMA, Aldrich, 1 equiv) and 
4-dimethylaminopyridine (DMAP, Aldrich, 0.1 equiv) were also added to the reaction 
mixture. Dicyclohexylcarbodiimide (DCC, Fluka, 1 equiv) was then added dropwise under 
continuous stirring and N2 (g) atmosphere. The resultant solution was stirred for 24h at room 
temperature. The reaction product was filtered to eliminate N,N’-diciclohexylurea formed salt 
and the organic phase was washed with water and a saturated solution of NaHCO3 (Panreac). 
Formerly, the resultant solution was dried with a saturated NaCl (Panreac) solution and 
anhydrous MgSO4 (Qemical) and finally, DCM was evaporated under reduced pressure. The 
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chemical structure and purity of HNAP was elucidated by 
1
H-NMR spectroscopy dissolving 
sample in deuterated chloroform (CDCl3, Sigma-Aldrich).  
Synthesis and characterization of copolymers of naproxen-based methacrylic monomer and 
1-vinyl imidazole, poly(HNAP-co-VI). Copolymeric systems based on HNAP were 
synthesized by free radical polymerization in solution using 1-vinylimidazole (VI, Aldrich) as 
co-monomer (Scheme 1). Three HNAP:VI feed molar ratios (i.e. 20:80, 50:50, 80:20) were 
tested. Moreover, two initial monomers concentrations were used: 0.5 м and 0.25 м. The 
copolymers were named HNAP followed by their molar content in this monomer. Particularly, 
comonomers were dissolved in dimethylsulfoxide (DMSO, Scharlau) at a total monomer 
concentration of 0.5 м or 0.25 м, and the reaction mixtures were deoxygenated with N2 (g) for 
10 minutes. Then, 2,2’-azobisisobutyronitrile (AIBN, Merck, 1.5 × 10-2 м) was to the solution 
and the reaction vessel was transferred to an oven at 60 ºC for 12 hours. Copolymerization 
mixtures were purified by dialysis (Spectrum Laboratories, 3.5 KDa molecular weight cut-off) 
against distilled water for 72 hours. Copolymers were isolated by freeze-drying as a white 
powder. Copolymers molar composition, molecular weight and polidispersity of molecular 
weight distribution and, glass transition temperature were determined by 
1
H-NMR, SEC and 
DSC, respectively (Supplementary Information). 
Determination of reactivity ratios. Reactivity ratios of the comonomers were determined by 
“in situ” 1H-NMR monitorization of the copolymerization reaction according to a previously 
described protocol. 
[35]
 Briefly, copolymerization reactions (FHNAP = 0.20, 0.40 and 0.60; [M] 
= 0.25 м and [AIBN] = 0.015 м) were carried out inside a NMR tube in the same experimental 
conditions as described above but using deuterated DMSO (DMSO-d6, Merck) as a solvent. A 
solution of DMF (10 mgmL-1) in DMSO-d6 in a thin wall capillary tube introduced in the 
NMR tube was used as reference. Temperature was maintained at 60 °C using the apparatus 
(Varian Mercury 400 MHz) heat control system. Signals were integrated using MestreNova 
9.0 software and reactivity ratios were determined using the methodology described by 
Aguilar, M.R. et al. in 2002. 
[35]
  
Preparation and characterization of self-assembled nanoparticles. Self-assembled NPs were 
prepared via nanoprecipitation method. Briefly, copolymers were dissolved in a 8:2 (v:v, 
acetone:ethanol, Scharlau) solvents mixture at a concentration of 10 mgmL
-1
 and then added 
dropwise over a continuously stirred aqueous buffer solution at pH 4 (0.1 м Acetic Acid and 
100 mм NaCl), a pH below the reported pKb of VI (i.e. 5.5-6.1). 
[56, 57]
 The resultant 
suspension was stirred overnight to evaporate remaining organic solvent. NPs were stored in 
suspension at 4 ºC. Hydrodynamic properties of NP suspension obtained by nanoprecipitation 
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of the high molecular weight and the low molecular weight copolymers (HNAP26, HNAP60, 
HNAP84, and HNAP24, HNAP71, HNAP85, respectively) were measured right after 
preparation of NPs to optimize hydrophobic-hydrophilic balance for NPs self-assembly in 
aqueous medium. In order to establish proper preparation conditions of NPs, NP-L-HNAP71 
hydrodynamic properties were also measured at different final concentrations of NPs in 
aqueous suspension ([NPs]F = 1 mgmL
-1
 and 5 mgmL-1) and final volumes of the aqueous 
phase (VF = 10 mL, 20 mL and 30 mL). In addition, to establish proper storage conditions, 
they were measured at different pH values (4.0, 4.5, 5.0 and, 5.5) and time-points (0 days, 7 
days, 14 days, 21 days and, 28 days) (see supplementary information for detailed 
explanation). In particular, the particle size distribution of the NP suspensionwas determined 
by dynamic light scattering (DLS) using a Malvern Nanosizer NanoZS Instrument equipped 
with a 4 mW He-Ne laser (λ = 633 nm) at a scattering angle of 173°. Measurements of NP 
dispersions were performed in square polystyrene cuvettes (SARSTEDT) and the temperature 
was kept constant at 25 °C. The autocorrelation function was converted in an intensity particle 
size distribution with ZetaSizer Software 7.10 version, to get the mean hydrodynamic 
diameter (Dh) and the particle dispersion index (PdI) between 0 (monodisperse particles) and 
1 (polydisperse particles) based on the Stokes−Einstein equation, assuming the particles to be 
spherical. For each sample, the statistical average and standard deviation of data were 
calculated from 3 measurements of 11 runs each one. The zeta potential (ξ) of NP dispersions 
was determined by laser Doppler electrophoresis (LDE) using a Malvern Nanosizer NanoZS 
Instrument. The ξ statistical average and standard deviations were calculated from 3 
measurements of 20 runs each one. Finally, scanning electron macroscopy (SEM) analysis of 
HNAP71 unloaded NPs was performed (supplementary information). 
Dexamethasone encapsulation. Dexamethasone (Dx, ≥98% pure; Aldrich, CAS Number: 50-
02-2)-loaded NPs were also prepared by nanoprecipitation method. Dx (15% w/w with 
respect to the polymer) and the corresponding polymer (10 mgmL-1) were dissolved in a 
mixture 8:2 (v:v) acetone:ethanol and added dropwise to the previously mentioned aqueous 
buffer solution at pH 4 under magnetic stirring. The final polymer concentration was 3.0 
mgmL
-1
. The solution was dialyzed against 0.1 м Acetic Acid, 100 mм NaCl aqueous solution 
at pH 4 for 72h in order to eliminate the organic solvent and soluble non-encapsulated Dx. 
The resultant NPs were filtered through 1 μm Nylon filters to remove remaining insoluble Dx. 
Encapsulation efficiency (%EE) and Loading Capacity (%LC). Dx-loaded NPs were freeze 
dried in order to eliminate aqueous phase. The obtained white amorphous powder was 
dissolved in 2 ml of a mixture 8:2 (v:v) acetone:ethanol to disassembly the nanoparticulated 
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structure and release the encapsulated drug; and the organic solvent is let to evaporate 
overnight. After that, the copolymer-Dx mixture was dissolved in a mixture acetonitrile:water 
(v:v, 8:2) to precipitate the polymer. Samples were centrifuged at 10.000 rpm for 5 minutes at 
RT and supernatant was analyzed by HPLC (Dx, λabs = 239 nm). The encapsulation efficiency 
(EE) was defined as the ratio of detected experimentally and original concentration of Dx 
encapsulated in the inner core of the NP (Equation 1) and the loading capacity as the ratio of 
mass of Dx detected and mass of NPs (Equation 2). 
Encapsulation Efficiency (%) =  
[Dx]measured
[Dx]initial
 × 100 (1) 
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑦 (%) =  
𝑚𝑎𝑠𝑠 𝑜𝑓 𝐷𝑥 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑁𝑃𝑠
×  100 (2) 
Cell culture. The RAW264.7 (murine macrophages) cell line was purchased from Sigma-
Aldrich. Cells were maintained over permissive conditions in high-glucose Dulbecco’s 
modified Eagle’s medium (DMEM; Sigma, Saint Louis, MO, USA) supplemented with 10% 
fetal bovine serum (FBS; Gibco, BRL), 2% L-Glutamine (Sigma, Saint Louis, MO, USA) and 
Penicillin-G (Sigma, Saint Louis, MO, USA) at 37 ˚C in a humidified incubator with 5% CO2. 
Uptake of c6-labelled NPs by macrophages. C6-loaded NPs were used as a model to study 
macrophage uptake of the NPs in cell culture. RAW264.7 cells were seeded into 6 well-plates 
(1.7 x 10
5 cellsmL-1), in complete DMEM. The cells were incubated overnight at 37 ˚C and 
5% CO2. The medium was replaced with the corresponding NP suspension in DMEM 
(NPs:DMEM (1:5)) and incubated over different times from 1h to 24h at 37 ˚C. Cells were 
harvested (and counted to normalize fluorescence/cell) at 1, 2, 4, 6, 8 and 24h after NPs 
addition, and were washed with cold PBS and centrifuged at 10.000 rpm. Supernatant was 
discarded and cell’s pellet was lysate with ethanol to free internalized c6. Fluorescence of 
supernatant at 458/540 nm (excitation/emission) was measured by a Multi-Detection 
Microplate Reader Synergy HT (BioTek Instruments; Vermont, USA).  
In vitro cytotoxicity assay of NPs. 2 x 10
5
 live cellsmL-1 (100 µL per well) were seeded in a 
96 well-plate under permissive conditions. After 24h, cells were exposed to different 
concentrations of unloaded NAP NPs, 8Dx-NAP NPs suspension (0.25, 0.125, 0.09, 0.045, 
0.023 and, 0.011 mgmL
-1
), or free Dx; and cell viability was determined after 24h of 
incubation. AlamarBlue (Invitrogen) was used to determine cell viability. Absorbance at 570 
nm was measured by a Multi-Detection Microplate Reader Synergy HT (BioTek Instruments; 
Vermont, USA). The treatments were done in replicates (n = 8). Results of the experiments 
were expressed as percentage of relative cell viability (% respect to the control). 
Test anti-inflammatory activity of NPs 
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Nitric Oxide (NO) assay. Briefly, 2 x 10
5
 live cellsmL-1 (100 µL per well) were seeded in a 
96 well-plate under permissive conditions. After 24h cells were treated with 
lipopolysaccharide (LPS, 5 μgmL-1; from Escherichia coli O111:B4; CAS Number: 297-473-
0, Aldrich) and with different [NPs]F (0.125, 0.09, 0.045, 0.023, 0.011 mgmL
-1
) of unloaded 
NAP NPs, 8Dx-NAP NPs or free Dx at the concentration that is encapsulated on each sample. 
24h after free Dx or NPs addition, LPS-induced NO release was evaluated using Griess 
reagent kit (Aldrich) in order to determine the anti-inflammatory capacity of the developed 
formulations. Basically, during the Griess reaction dinitrogen trioxide (N2O3) generated from 
the acid-catalyzed formation of nitrous acid from nitrite (or autoxidation of NO) reacts with 
sulfanilamide to produce a diazonium ion which is then coupled to N-(1-napthyl) 
ethylenediamine to form a chromophoric azo product that absorbs strongly at 540 nm. The 
treatments were done in replicates (n = 8). Results were expressed as percentage of relative 
NO released (% respect to the control, cell activated with LPS (LPS+)) normalized by the 
number of cells obtained by Alamar Blue assay and considering NO level of cells activated 
with LPS (LPS+) 100%. 
RNA extraction, reverse transcription, real-time quantitative PCR (RT-qPCR). The 
transcription of M1 (Il12b, Il23a, and Tnfa), M2 (Tgfb1, and Il10) and pro-angiogenic (Vegfa) 
related genes were investigated by quantitative RT-PCR.  RAW264.7 cells were incubated 
24h with or without LPS (500 ngmL
-1
) and either non-treated (LPS-) or treated with unloaded 
NAP-NPs (0.045 mgmL
-1
), 8%Dx-NAP-NPs (2.55 μм Dx and 0.045 mgmL-1 NPs) or free Dx 
(2.55 μм). After 24h, macrophages were washed with medium to eliminate non-internalized 
NPs or free Dx from the culture media and incubated in culture medium up to seven days. At 
day 1 and day 7, total RNA was extracted from cells using the PureLink RNA Mini Kit 
(Applied Biosystems) following manufacturer's instructions. 
[58]
 RNA concentration was 
determined by absorbance measurements at 260 and 280 nm in a NanoDrop 1000 
spectrophotometer (Thermo Scientific) and 40 ng RNA/sample were converted into cDNA 
using a MultiScribe reverse transcription-based reaction kit (Applied Biosystems) in the 
presence of a RNAse inhibitor (N8080119, Applied Biosystems) in a MyCycler thermocycler 
(Bio-Rad; with the following temperature profile: 25 ºC-10 min, 37 ºC-2h, 85 ºC-5 min, 4 ºC 
∞). Specific primers were used for quantitative PCR. The list of specific primers used (all 
from Sigma) is provided in Table 5.  The reaction was performed using the Power SYBR 
Green PCR Master Mix (Applied Biosystems), in an ABI PRISM 7900HT Real-Time PCR 
System (Applied Biosystems; with the following temperature profile: 95 ºC-15 s, 60 ºC-60 s, 
40 cycles). Melting curves were generated in order to verify the specificity of the 
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amplification (15 s, from 60 ºC to 95 ºC). RT-qPCR expression data were analyzed according 
to the 2
−ΔΔCt
 method 
[58]
 or as 2
−ΔCt
 normalized to β-actin.  For global analysis, x fold change 
values were translated to a heat map representation with MeV software (Institute for Genomic 
Research, Rockville MD). Two-way analysis of variance (ANOVA) and Tukey test were 
applied to calculate the differences between the values. Values of p < 0.05 were considered 
statistically significant. The levels of significance are presented as * (p < 0.05), ** (p < 0.01) 
and *** (p < 0.001). All quantifications were performed in triplicate.  
 
Table 5. RT-qPCR primer list 
Gene 
Symbol 
Official        Full 
Name 
Species Forward (5’-3’) Reverse (5’-3’) 
Il23a Interleukin-23 
subunit alpha 
mouse AATAATGCTATGGCTGTTGC CTTAGTAGATTCATATGTCCCG 
Tnfa Tumor necrosis 
factor 
mouse CTATGTCTCAGCCTCTTCTC CATTTGGGAACTTCTCATCC 
Il12b Interleukin-12 
subunit beta 
mouse CATCAGGGACATCATCAAAC CTCTGTCTCCTTCATCTTTTC 
Vegfa Vascular 
endothelial growth 
factor A 
mouse TAGAGTACATCTTCAAGCCG TCTTTCTTTGGTCTGCATTC 
Tgfb1 Transforming 
growth factor 
beta-1 proprotein 
mouse GGATACCAACTATTGCTTCAG TGTCCAGGCTCCAAATATAG 
Il10 Interleukin-10 mouse CAGGACTTTAAGGGTTACTTG ATTTTCACAGGGGAGAAATC 
Actb Actin, beta mouse GATGTATGAAGGCTTTGGTC TGTGCACTTTTATTGGTCTC 
 
Supporting Information  
Supporting Information is available from the Wiley Online Library or from the author. 
Detailed information of materials and methods; and results and discussion. Table S1. 
Summary of encapsulation efficiency, loading capacity and hydrodynamic properties of 
unloaded, coumarin-6-loaded and dexamethasone-loaded nanoparticles prepared with L-
HNAP71 copolymer. Figure S1. Surface diagrams representing the variation of the 
instantaneous molar fraction of HNAP in the copolymer. Table S2. Quantitative real-time 
PCR data. Gene transcript levels of M1 and M2 markers (with or without LPS), treated with 
free dexamethasone (free Dx, 2.55 μм), Dx-loaded naproxen-bearing NPs (8Dx-NAP NPs, 
2.55μм Dx and 0.045 mgmL-1 NPs) and unloaded naproxen-bearing NPs (NAP NPs, 0.045 
mgmL
-1
) for 1 day or 7 days. Data are presented as mean and standard deviation (mean ± SD) 
of the average log2 variation compared to untreated cells (LPS-) in 3 independent experiments, 
each quantified in triplicate (see Figure 8 and 9). 
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Materials and methods 
Synthesis and characterization of copolymers of naproxen-based methacrylic monomer and 
1-vinyl imidazole, poly(HNAP-co-VI). 
Proton Nuclear Magnetic Resonance (
1
H-NMR) of the obtained copolymers were performed 
in a Varian Mercury apparatus operating at 400 MHz. Spectra were recorded by dissolving the 
samples in DMSO-d6 at 25 ºC. Copolymers composition was calculated using MestreNova 9.0 
from the 
1
H-NMR integral between 7.92-6.47 ppm corresponding to the aromatic protons of 
both monomers and the integral between 2.28-0.1 ppm which corresponds to protons of the 
methyl groups i and m of HNAP and protons l and n from the main hydrophobic carbon chain 
of HNAP and VI, respectively (figure 2).  
Size exclusion chromatography (SEC). Copolymers apparent average molecular weight (Mn 
and Mw) and polydispersity index (Ð) were determined by size exclusion chromatography 
(SEC), using a Perkin-Elmer Isocratic LC pump 250 coupled to a refraction index detector 
(Series 200). Two Resipore columns (250 mm x 4.6 mm, Varian) were used as solid phase, 
and degassed chromatographic grade dimethylformamide (DMF, Scharlab, 0.7 mLmin-1) with 
LiBr (0.1 % w/v) was used as eluent and temperature was fixed at 70 ºC. Monodisperse 
PMMA standards (Scharlab) with molecular weights between 10,300 and 1,400,000 Da were 
used to obtain the calibration curve. Data was analyzed using the Perkin-Elmer LC solution 
program.  
Differential scanning calorimetry (DSC). Glass transition temperatures (Tg) were determined 
by differential scanning calorimetry (DSC) with a Perkin Elmer DSC8500 interfaced to a 
Pyris thermal analysis data system. Dried samples (3-5 mg) were placed in aluminium pans 
and heated from -20 to 120 ºC (200 ºC in case of poly(VI)) at a constant speed of 20 ºCmin
-1
. 
Tg was taken as the midpoint of the heat capacity transition. 
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Preparation and characterization of self-assembled nanoparticles  
Scanning electron microscopy NPs morphology characterization 
To determine NPs shape, a SEM analysis of HNAP71 unloaded NPs was performed with a 
Hitachi SU8000 TED, cold-emission FE-SEM microscope working with an accelerating 
voltage 1 kV-D. Sample preparation consisted in the deposition of one drop of the 
corresponding NPs suspension (0.02 mgmL-1) over a small glass disk (12 mm diameter) and 
evaporation at room temperature. Gold palladium alloy (80:20) was used to coat the samples 
prior to examination by SEM. 
 
Optimization of final NP concentration ([NPs]F) and final volume (VF) 
Different final concentrations of NPs in aqueous suspension ([NPs]F = 1 mgmL
-1
 and 5 
mgmL-1) and three different final volumes of the aqueous phase (VF = 10 mL, 20 mL and 30 
mL) were tested. Hydrodynamic properties were measured to determine the largest volume 
and final concentration that can be prepared keeping hydrodynamic properties within the 
appropriate ranges for cell uptake by inflammatory cells. 
Optimization of storage conditions 
A pH study was performed to determine the aggregation pH of the systems and set the 
appropriate storage pH. NPs were prepared at pH = 4.0 and hydrodynamic properties were 
measured. pH was increased by 0.5 via the addition of 1 м NaOH aqueous solution and size 
distribution and ξ were measured. The procedure was repeated until the aggregation pH was 
reached. After that, the pH was set to 4.0 again to check reversibility of the aggregation 
phenomenon. Samples size distribution and ξ were measured every week up to one month to 
demonstrate NPs stability when stored in suspension at 4 °C and at the most suitable storage 
pH. NPs were freeze-dried after preparation and dispersed in the same volume of 0.1 м acetic 
acid buffer solution. The suspension was then subjected to manual shaking and ultrasound 
bath/tip sonication (30 % amplitude) for 10 minutes. After sonication, size distribution of NPs 
was measured to check redispersibility. 
Preparation of c6-loaded NPs 
Coumarin-6(c6)-loaded NPs were also prepared by nanoprecipitation method. c6 (Aldrich, 
1% w/w with respect to the polymer) and the corresponding polymer (10 mgmL
-1
) were 
dissolved in a mixture 8:2 (v:v, acetone:ethanol) and added dropwise to the aqueous buffer 
solution (0.1 м NaCl, 0.1 м Acetic Acid) at pH 4 under magnetic stirring. The final polymer 
concentration was 3.0 mgmL
-1
. The solution was dialyzed against the same aqueous buffer 
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solution at pH 4 for 72h in order to eliminate the organic solvent and soluble non-
encapsulated c6. The resultant NPs were filtered through 1 μm Nylon filters to remove 
remaining insoluble c6. 
C6 encapsulation efficiency (%EE) and Loading Capacity (%LC) 
c6-loaded NPs were freeze dried in order to eliminate aqueous phase. The obtained white 
amorphous powder was dissolved in 2 ml of a mixture 8:2 (v:v) acetone:ethanol to 
disassembly the nanoparticulated structure and release the encapsulated drug; and the organic 
solvent is let to evaporate overnight. After that, the copolymer-c6 samples in ethanol to 
precipitate the polymer. Samples were centrifuged at 10.000 rpm for 5 minutes at RT and 
supernatant was analyzed by UV spectrophotometry (c6, λabs = 459 nm). The encapsulation 
efficiency (EE) was defined as the ratio of detected experimentally and original concentration 
of c6 encapsulated in the inner core of the NP (Equation 1S) and the loading capacity as the 
ratio of mass of c6 detected and mass of NPs (Equation 2S). 
Encapsulation Efficiency (%) =  
[c6]measured
[c6]initial
 × 100 (1S) 
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑦 (%) =  
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑐6 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑁𝑃𝑠
×  100 (2S) 
 
Results 
C6-loaded NPs to monitor cellular uptake of NPs 
C6 was used as a fluorescent probe in NPs internalization cellular studies. HNAP71-based 
NPs encapsulate c6 with low loading capacity (%LC = 0.92) to avoid fluorescence quenching 
of the signal. Encapsulation efficiency higher than 90% was achieved (Encapsulation 
Efficiency (%EE) = 92%) and only an increase in 10 nm on the NPs diameter was observed 
with no significant changes in surface charge (table S1). 
 
Table S1. Summary of encapsulation efficiency, loading capacity and hydrodynamic 
properties of unloaded, coumarin-6-loaded and dexamethasone-loaded nanoparticles prepared 
with L-HNAP71 copolymer 
Acronym Sample EE
a)
 [%] LC
b)
 [%] D
h
c) [nm] PdI
d)
 ξ
e)
 [mV] 
NAP NPs NP-L-HNAP71 - - 131.5 ± 3.3 0.115 ± 0.016 + 28.8 ± 0.7 
Dx-NAP NPs 8Dx-NP-L-HNAP71 8  2.00 149.5 ± 1.8 0.085 ± 0.018 + 26.1 ± 0.9 
c6-NAP NPs 92c6-NP-L-HNAP71 92  0.92 140.0 ± 1.1 0.132 ± 0.026 + 28.9 ± 0.6 
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 a)Encapsulation Efficiency, b)Loading capacity, c)hydrodynamic diameter, d)polydispersity and e)zeta 
potential 
 
Figure S1. Surface diagrams representing the variation of the instantaneous molar fraction of 
HNAP in the copolymer. 
Table S2. Quantitative real-time PCR data. Gene transcript levels of M1 and M2 markers (with 
or without LPS), treated with free dexamethasone (free Dx, 2.55 μм), Dx-loaded naproxen-
bearing NPs (8Dx-NAP NPs, 2.55μм Dx and 0.045 mgmL-1 NPs) and unloaded naproxen-
bearing NPs (NAP NPs, 0.045 mgmL
-1
) for 1 day or 7 days. Data are presented as mean and 
standard deviation (mean ± SD) of the average log2 variation compared to untreated cells in 3 
independent experiments, each quantified in triplicate (see Figure 8a, figure8b and figure 
9a). 
 
M1 and M2 markers (LPS-) 
Genes Free Dx 8Dx-NAP NPs NAP NPs 
 
Il23a (M1) 
Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 
0.40 ± 0,21 0.82 ± 0.45 0.07 ± 0.02 0.29 ± 0.13 -0.18 ± 0.10 0.37 ± 0.24 
Il12b (M1) -0.19 ± 0.06 -0.18 ± 0.08 -12.28 ± 0.04 -12.19 ± 0.27 -0.34 ± 0.17 0.05 ± 0.01 
Tnfa (M1) 0.16 ± 0.07 0.51 ± 0.01 0.04 ± 0.01 0.67 ± 0.40 -0.09 ± 0.01 0.46 ± 0.33 
Vegfa (M2) 0.28 ± 0.16 -1.22 ± 0.03 0.42 ± 0.35 -0.04 ± 0.02 -0.28 ± 0.17 0.09 ± 0.01 
Tgfb1 (M2) 0.13 ± 0.03 -0.15 ± 0.07 -0.08 ± 0.02 -0.02 ± 0.01 -0.56 ± 0.50 0.04 ± 0.02 
Il10 (M2) -1.70 ± 0.84 -0.89 ± 0.03 -0.15 ± 0.05 -0.43 ± 0.20 -0.40 ±0.21 0.05 ± 0.01 
 
 
M1 markers (LPS+) 
Genes CP (+LPS) Free Dx 8Dx-NAP NPs NAP NPs 
Il23a Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 
1.54 ± 0.03 -2.78 ± 0.25 0.69 ± 0.12 0.24 ± 0.06 0.53 ± 0.38 0.88 ± 0.10 1.54 ± 0.33 -2.77 ± 0.07 
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Il12b 0.17 ± 0.02 3.51 ± 0.01 -0.40 ± 0.01 -0.06 ± 0.01 -12.33 ± 0.01 -12.1± 0.28 0.17 ± 0.02 3.51 ± 0.14 
Tnfa 3.70 ± 0.28 0.91 ± 0.01 0.60 ± 0.12 0.59 ± 0.21 0.73 ± 0.12 1.18 ± 0.10 3.71 ± 0.70 0.91 ± 0.03 
 
 
